Altered Glucagon and GLP-1 Responses to Oral Glucose in Children and Adolescents With Obesity and Insulin Resistance.

Autor: Stinson, Sara Elizabeth, Alzola, Ierai Fernández de Retana, Hovendal, Emilie Damgaard Brünner, Lund, Morten Asp Vonsild, Fonvig, Cilius Esmann, Holm, Louise Aas, Jonsson, Anna Elisabet, Frithioff-Bøjsøe, Christine, Christiansen, Michael, Pedersen, Oluf, Ängquist, Lars, Sørensen, Thorkild I A, Holst, Jens Juul, Hartmann, Bolette, Holm, Jens-Christian, Hansen, Torben

Publikováno v: Journal of Clinical Endocrinology & Metabolism; Jun2024, Vol. 109 Issue 6, p1590-1600, 11p

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Autor: Engelbrechtsen, Line, Lundgren, J, Wewer Albrechtsen, Nicolai Jacob, Mahendran, Yuvaraj, Iepsen, Eva Pers Winning, Finocchietto, P., Jonsson, Anna Elisabet, Madsbad, Sten, Holst, Jens Juul, Vestergaard, Henrik, Hansen, T., Torekov, Signe Sørensen

Publikováno v: Engelbrechtsen, L, Lundgren, J, Wewer Albrechtsen, N J, Mahendran, Y, Iepsen, E P W, Finocchietto, P, Jonsson, A E, Madsbad, S, Holst, J J, Vestergaard, H, Hansen, T & Torekov, S S 2017, ' Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB ', Obesity Science & Practice, vol. 3, no. 4, pp. 425-433 . https://doi.org/10.1002/osp4.133

Background: Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight main

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2751::cb2cb18ae563a4fe0e9c7394e27acd74
https://curis.ku.dk/ws/files/191189609/Treatment_with_liraglutide_may_improve_markers_of_CVD_reflected_by_reduced_levels_of_apoB.pdf